Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797202 | 1.00 | PYGL (0.55) | PYGLCCKBR | |
| SCHEMBL7421691 | 0.90 | CCKBR (0.51) | CCKBR | |
| SCHEMBL7421660 | 0.90 | ACE (0.57) | PYGLCCKBR | |
| SCHEMBL7422474 | 0.89 | CCKBR (0.50) | PYGLCCKBR | |
| SCHEMBL7421751 | 0.89 | PYGL (0.52) | PYGLCCKBR | |
| SCHEMBL8888599 | 0.89 | CCKBR (0.49) | PYGLCCKBR | |
| SCHEMBL7421160 | 0.89 | SCN9A (0.48) | CCKBR | |
| SCHEMBL7424675 | 0.88 | CCKBR (0.47) | PYGLCCKBR | |
| SCHEMBL7418735 | 0.88 | PYGL (0.54) | PYGLCCKBR | |
| SCHEMBL7423984 | 0.88 | SCN9A (0.50) | CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425550-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2008-09-16 | — | — | US | disclosed |
| US-7098235-B2 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | SHER PHILIP | 2006-06-15 | — | — | US | disclosed |
| US-7057046-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | PYGL, PNLIP, PYGM | PYGL 1/4885CCKBR 1749/4885 |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS2 | PYGL 1/4885CCKBR 3021/4885 |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS1 | PYGL 1/4885CCKBR 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.